CancerGuide Diagnostics Secures $10.5 Million Private Financing Agreement

Bookmark and Share

DURHAM, N.C.--(BUSINESS WIRE)--CancerGuide Diagnostics™, Inc. (CancerGuide), which develops and markets tests to support individualized cancer therapy decisions, today announced that it has completed the first tranche of a $10.5 million round of private financing and signed a multi-year, strategic collaboration and license agreement with Laboratory Corporation of America Holdings (LabCorp). The financing was co-led by Hatteras Venture Partners and Intersouth Partners. LabCorp also is participating in the financing as an equity investor.

Under the agreement, LabCorp and CancerGuide will collaborate in the development and commercialization of CancerGuide’s molecular oncology assays.

“Cancer is an extremely complex disease that accounts for almost one out of every four deaths in the United States. There is a tremendous need for diagnostic tools to optimize the management of the disease and take full advantage of available therapeutic options,” said Myla Lai-Goldman, M.D., CancerGuide CEO. “Through our unique partnership model, CancerGuide will provide companion diagnostic development services to pharmaceutical and biotechnology companies to maximize the efficiency and effectiveness of the market entry strategies. CancerGuide is committed to helping bring these life-saving, personalized medicine products and services to market.”

“We are pleased to be a CancerGuide lead investor. CancerGuide’s high value testing services will provide anxiously-waiting oncologists, pathologists, and researchers with the information necessary to prescribe the right drug for the right patient – thereby saving lives while reducing the costs of care and drug development,” said Garheng Kong, M.D., General Partner of Intersouth Partners. “CancerGuide’s distinctive combination of resources and partnerships will make the company a highly-sought after commercialization platform for novel molecular oncology technologies.”

“CancerGuide is a uniquely-positioned company, with the optimal management team and a formidable strategic partner,” stated Clay Thorp, General Partner of Hatteras. “The company’s team and partnership model create a great investment proposition by enabling us to bring compelling cancer treatment tests and services to market more rapidly than we could otherwise.”

About CancerGuide

CancerGuide Diagnostics, founded in 2006, is a life science company focused on the development and commercialization of genomic-based clinical and pharmaceutical cancer tests and services, enabling physicians, patients, and researchers to make individualized treatment or drug discovery decisions. The CancerGuide management team is led by two former colleagues from LabCorp who have worked together for 18 years. Dr. Lai-Goldman is the retired CSO and CMO of LabCorp. She is a board-certified clinical and anatomic pathologist who pioneered the commercialization of several landmark technologies including PCR, HIV genotyping, and Her2/neu. Bill Haas is a diagnostic commercialization, operations and business development veteran, who was EVP of LabCorp’s Esoteric Business as well as EVP of Sales, Marketing and Managed Care. The leadership team also includes Judd Staples, who brings with him extensive experience in finance, business development and operations in early-stage life science companies. CancerGuide’s strategic partnership model and experienced management team lay the foundation for an unprecedented “speed-to-market” for personalized oncology diagnostic discoveries.

Further information of CancerGuide can be found on the website, www.cancerguidedx.com, or by calling 919.474.CGDX (2439).

Note: CancerGuide Diagnostics™ and related marks are pending registered trademarks of CancerGuide Diagnostics, Inc.

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to or implying forthcoming clinical products and the status of regulation by the U.S. Food and Drug Administration (FDA) of our test service. These forward-looking statements speak only as of the date hereof. CancerGuide disclaims any obligation to update these forward-looking statements.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6167870<=en

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6167870 Contact:

CancerGuide Diagnostics, Inc. Myla Lai-Goldman, CEO and CSO Bill Haas, President and COO Judd Staples, EVP Corporate Development 919-474-2439, inquiry@cancerguidedx.com

MORE ON THIS TOPIC